Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-Term Extension Study for Oral Levosimendan (TNX-103) in PH-HFpEF
NCT07436689Phase 3Enrolling by invitation
- Sponsor
- Tenax Therapeutics
- Start
- Mar 2026
- Primary completion
- Mar 2029
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of levosimendan in pulmonary hypertension (PH), sponsored by Tenax Therapeutics. Started Mar 2026; status: enrolling by invitation.
02
Drugs
levosimendan
03
Conditions
pulmonary hypertension (PH)
Beyond the preview
Go deeper on NCT07436689.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07436689.